An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD

Chest

Volumn 129, Issue 6, 2006, Pages 1693-1708

  D'Souza, Anna O ^a   Smith, Michael J ^a   Miller, Lesley Ann ^a   Kavookjian, Jan ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

COPD; COPD costs; COPD outcome measures; Pharmacoeconomics

Indexed keywords

BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

ADD ON THERAPY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DISEASE EXACERBATION; DRUG COST; FOLLOW UP; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAINTENANCE THERAPY; MEDLINE; OUTCOME ASSESSMENT; PHARMACOECONOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUESTIONNAIRE; SYSTEMATIC REVIEW;

EID: 33745116251     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.129.6.1693     Document Type: Article

References (51)

1. National Heart, Lung, and Blood Institute. Morbidity and mortality: 2004 chart book on cardiovascular, lung, and blood diseases. Available at: http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf. Accessed September 13, 2004
2. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163:1256-1276
3. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003; 58:659-664
4. Briggs DD Jr. Chronic obstructive pulmonary disease overview: prevalence, pathogenesis, and treatment. J Manag Care Pharm 2004; 10(suppl):S3-S10
5. O'Donnell DE. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117(suppl):42S-47S
6. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23:932-946
7. Hilleman DE, Dewan N, Malesker M, et al. Pharmacoeconomic evaluation of COPD. Chest 2000; 118:1278-1285
8. Jubran A, Gross N, Ramsdell J, et al. Comparative cost-effectiveness analysis of theophylline and ipratropium bromide in chronic obstructive pulmonary disease: a three-center study. Chest 1993; 103:678-684
9. Sclar DA, Legg RF, Skaer TL, et al. Ipratropium bromide in the management of chronic obstructive pulmonary disease: effect on health service expenditures. Clin Ther 1994; 16:595-601
10. Friedman M. Changing practices in COPD: a new pharmacologic treatment algorithm. Chest 1995; 107(suppl):194S-197S
11. Ramsey SD. Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000; 117(suppl):33S-37S
12. Ramsey SD, Sullivan SD. The burden of illness and economic evaluation for COPD. Eur Respir J Suppl 2003; 41:29s-35s
13. Basic types of economic evaluation. In: Drummond M, O'Brien BJ, Stoddart GL, et al, eds. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press, 1997; 2-26
14. Cost-effectiveness analysis. In: Drummond M, O'Brien BJ, Stoddart GL, et al, eds. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press, 1997; 96-138
15. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10:212-214
16. O'Brien BJ, Drummond MF, Labelle RJ, et al. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150-163
17. Coyle D. Statistical analysis in pharmacoeconomic studies: a review of current issues and standards. Pharmacoeconomics 1996; 9:506-516
18. Collection and analysis of data. In: Drummond M, O'Brien BJ, Stoddart GL, et al, eds. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press, 1997; 232-264
19. van Hout BA, Al MJ, Gordon GS, et al. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3:309-319
20. Jacobs P, Bachynsky J, Baladi JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995; 8:182-189
21. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines-similarities, differences and some implications. Value Health 2001; 4:225-250
22. Critical assessment of economic evaluation. In: Drummond M, O'Brien BJ, Stoddart GL, et al, eds. Methods for the economic evaluation of health care programmes. New York, NY: Oxford University Press, 1997; 27-51
23. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115:635-641
24. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial; COMBIVENT Inhalation Aerosol Study Group. Chest 1994; 105:1411-1419
25. Hogan TJ, Geddes R, Gonzalez ER. An economic assessment of inhaled formoterol dry powder versus ipratropium bromide pressurized metered dose inhaler in the treatment of chronic obstructive pulmonary disease. Clin Ther 2003; 25:285-297
26. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784
27. Jones PW, Wilson K, Sondhi S. Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med 2003; 97:20-26
28. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10:815-821
29. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
30. Oostenbrink JB, Al MJ, Rutten-van Molken MP. Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics 2003; 21:1103-1112
31. Ayres JG, Price MJ, Efthimiou J. Cost-effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial. Respir Med 2003; 97:212-220
32. Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351:773-780
33. Oostenbrink JB, Rutten-van Molken MP, Al MJ, et al. One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J 2004; 23:241-249
34. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19:209-216
35. Sin DD, Golmohammadi K, Jacobs P. Cost-effectiveness of inhaled corticosteroids for chronic obstructive pulmonary disease according to disease severity. Am J Med 2004; 116:325-331
36. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152:877-8121
37. 1: the Lung Health Study. JAMA; 272:1497-1505
38. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003; 58:937-941
39. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113:59-65
40. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003; 41:46s-53s
41. Wedzicha JA, Donaldson GC. Exacerbations of chronic obstructive pulmonary disease. Respir Care 2003; 48:1204-1213
42. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(suppl):398S-401S
43. Liljas B. How to calculate indirect costs in economic evaluations. Pharmacoeconomics 1998; 13:1-7
44. Coyle D, Lee KM. The problem of protocol driven costs in pharmacoeconomic analysis. Pharmacoeconomics 1998; 14:357-363
45. GOLD, Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease updated 2004: NHLBI/WHO workshop report. 2004 Available at: www.goldcopd.org/. Accessed January 15, 2005
46. Tashkin DP, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest 2004; 125:249-259
47. Sin DD, Man SF. Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter? Eur Respir J 2003; 21:260-266
48. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:580-584
49. Soriano JB, Kin VA, Pride NB, et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2003; 2:67-74
50. de Melo MN, Ernst P, Suissa S. Inhaled corticosteroids and the risk of a first exacerbation in COPD patients. Eur Respir J 2004; 23:692-697
51. Fan VS, Bryson CL, Curtis JR, et al. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis. Am J Respir Crit Care Med 2003; 168:1488-1494